TRIM33 and neoplasm: For example, in triple-negative breast cancer, KAT6A promotes interactions between SMAD3 and TRIM24 by mediating SMAD3 acetylation and inhibiting interactions between SMAD3 and TRIM33, thereby promoting tumor progression by regulating the immune microenvironment [31].